Department of Biomedical Sciences, Humanitas University, 20090, Pieve Emanuele, Milan, Italy.
Department of Emergency Medicine, Humanitas Clinical and Research Center-IRCCS, 20089, Rozzano, Milan, Italy.
Intern Emerg Med. 2021 Oct;16(7):1857-1864. doi: 10.1007/s11739-021-02714-y. Epub 2021 Mar 26.
COVID-19 diagnosis relies on molecular testing for SARS-CoV-2 via nasopharyngeal swab in the presence of suggestive clinical, radiological and laboratory findings. Since bronchoalveolar lavage liquid (BAL) collected during fibrobronchoscopy may increase test sensitivity compared to nasopharyngeal swabs, it was performed during the 2020 pandemic in clinically or radiologically suspected cases. Our aim was to determine whether clinical features, chest computed tomography (CT) findings or laboratory tests may predict patients testing positive for SARS-CoV-2 at BAL after a negative nasopharyngeal swab. We performed a retrospective cross-sectional study with multivariable analysis of suspected patients who were tested for SARS-CoV-2 at BAL after at least one negative nasopharyngeal swab. Univariable logistic regression for odds ratio and multivariate models was calculated to determine clinical, radiological and laboratory predictors. 32/198 (16%) patients had BAL positive for SARS-CoV-2, while 65/198 tested positive for other pathogens at BAL. Of the 32 patients positive for COVID, 4 had a coinfection at BAL, being thus positive both for COVID as well as for another pathogen while the remaining 105 patients were negative for COVID and other pathogens at BAL. COVID-19 patients had more often highly suggestive CT findings, higher number of involved lobes, more often ground glass opacity of more than 50% of lung parenchyma, and less frequently other radiologically suspected infections. At multivariate model, temperature also predicted BAL positivity. The procedure was well tolerated-with only one desaturation episode-while no healthcare worker was infected. In conclusion, when nasopharyngeal swabs are negative but there is clinical or imaging suspicion of COVID-19, BAL represents a complementary diagnostic tool, particularly in conjunction with suggestive/more extensive lung involvement at CT scan. The procedure did not carry increased risks for patients nor for operators, while allowing to free hospital resources, avoiding unnecessary isolations.
COVID-19 的诊断依赖于在有提示性临床、放射学和实验室发现的情况下,通过鼻咽拭子对 SARS-CoV-2 进行分子检测。由于纤维支气管镜检查时收集的支气管肺泡灌洗液(BAL)与鼻咽拭子相比可能会提高检测敏感性,因此在 2020 年大流行期间对临床或放射学疑似病例进行了 BAL 检查。我们的目的是确定在鼻咽拭子阴性后,BAL 检测 SARS-CoV-2 阳性的患者是否具有临床特征、胸部计算机断层扫描(CT)表现或实验室检查结果。我们对至少进行过一次鼻咽拭子阴性检测后,对 BAL 进行 SARS-CoV-2 检测的疑似患者进行了回顾性横断面研究,并进行了多变量分析。使用单变量逻辑回归计算比值比和多变量模型,以确定临床、放射学和实验室预测因素。在 198 名患者中,有 32 名(16%)患者的 BAL 检测到 SARS-CoV-2 阳性,而 65 名患者的 BAL 检测到其他病原体阳性。在 32 名 COVID 阳性患者中,有 4 名 BAL 同时存在混合感染,即 COVID 和其他病原体均呈阳性,而其余 105 名患者的 BAL 检测结果均为 COVID 和其他病原体均为阴性。COVID-19 患者更常出现高度提示性 CT 表现,受累肺叶数更多,更常出现超过 50%肺实质磨玻璃影,而其他放射学疑似感染较少见。在多变量模型中,体温也可预测 BAL 阳性。该操作耐受性良好,仅出现 1 例低氧血症,且无医护人员感染。总之,当鼻咽拭子为阴性,但有 COVID-19 的临床或影像学怀疑时,BAL 是一种补充诊断工具,特别是与 CT 扫描提示性/更广泛的肺部受累相结合时。该操作不会增加患者和操作人员的风险,同时可以释放医院资源,避免不必要的隔离。